Dr Haiyan Zheng Dr Michael Grayling Professor James Wason
| Bayesian sample size determination in basket trials borrowing information between subsets | 2023 |
|
Dr Michael Grayling Professor James Wason
| Point estimation following a two-stage group sequential trial | 2023 |
|
Aritra Mukherjee Dr Michael Grayling Professor James Wason
| Adaptive designs: Benefits and cautions for neurosurgery trials | 2022 |
|
Helen Mossop Dr Michael Grayling Professor James Wason
| Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials | 2022 |
|
Dr Michael Grayling Dr Ben Shillitoe Dr Malcolm Brodlie Dr Louise Michaelis
| Characterising the allergic profile of children with cystic fibrosis | 2022 |
|
Dr Michael Grayling Professor James Wason
| Conditional power and friends: The why and how of (un)planned, unblinded sample size recalculations in confirmatory trials | 2022 |
|
Luke Ouma Professor James Wason Dr Haiyan Zheng Dr Nina Wilson Dr Michael Grayling et al. | Design and analysis of umbrella trials: Where do we stand? | 2022 |
|
Dr Michael Grayling Professor James Wason
| Response adaptive intervention allocation in stepped-wedge cluster randomized trials | 2022 |
|
Dr Michael Grayling Professor James Wason
| A Review of Bayesian Perspectives on Sample Size Derivation for Confirmatory Trials | 2021 |
|
Dr Graham McClelland Dr Nina Wilson Dr Lisa Shaw Dr Michael Grayling Professor Christopher Price et al. | Ambulance documentation of stroke symptoms during the UK COVID-19 ‘Stay at home’ message | 2021 |
|
Dr Michael Grayling Professor James Wason
| Exact group sequential designs for two-arm experiments with Poisson distributed outcome variables | 2021 |
|
Dr Michael Grayling Professor James Wason
| Increasing power in the analysis of responder endpoints in rheumatology: a software tutorial | 2021 |
|
Dr Michael Grayling Dr Theophile Bigirumurame Dr Svetlana Cherlin Luke Ouma Dr Haiyan Zheng et al. | Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential | 2021 |
|
Luke Ouma Dr Michael Grayling Dr Haiyan Zheng Professor James Wason
| Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods | 2021 |
|
Dr Michael Grayling Professor James Wason
| A web application for the design of multi-arm clinical trials | 2020 |
|
Dr Michael Grayling
| A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials | 2019 |
|
Dr Michael Grayling Professor James Wason
| Admissible multiarm stepped-wedge cluster randomized trial designs | 2019 |
|
Dr Michael Grayling
| Re-formulating Gehan's design as a flexible two-stage single-arm trial | 2019 |
|
Dr Michael Grayling Professor James Wason
| Two-Stage Adaptive Designs for Three-Treatment Bioequivalence Studies | 2019 |
|
Dr Michael Grayling Professor James Wason
| An optimised multi-arm multi-stage clinical trial design for unknown variance | 2018 |
|
Dr Michael Grayling Professor James Wason
| Blinded and unblinded sample size re-estimation in crossover trials balanced for period | 2018 |
|
Dr Michael Grayling Professor James Wason
| Blinded and unblinded sample size reestimation procedures for stepped-wedge cluster randomized trials | 2018 |
|
Dr Michael Grayling
| Calculations involving the multivariate normal and multivariate t distributions with and without truncation | 2018 |
|
Dr Michael Grayling Professor James Wason
| Group Sequential Clinical Trial Designs for Normally Distributed Outcome Variables | 2018 |
|
Dr Michael Grayling Professor James Wason
| Group sequential crossover trial designs with strong control of the familywise error rate | 2018 |
|
Dr Michael Grayling Professor Jeremy Grimshaw
| Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration | 2018 |
|
Dr Michael Grayling Professor James Wason
| Group sequential designs for stepped-wedge cluster randomised trials | 2017 |
|
Dr Michael Grayling Professor James Wason
| Stepped wedge cluster randomized controlled trial designs: A review of reporting quality and design features | 2017 |
|